Wednesday, July 23, 2014 Last update: 7:03 AM
FreshNews.com - All Company Technology News Since 1996

Sorrento Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference

Companies mentioned in this article: Sorrento Therapeutics, Inc.

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the ROTH Capital Partners 26(th) Annual Growth Stock Conference. The presentation will take place at noon PDT on Tuesday, March 11, in Salon 5 of the Ritz Carlton in Dana Point, Calif.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.sorrentotherapeutics.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq, the next-generation paclitaxel, will commence its registrational trial and be developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated ADC platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, therapeutic antibodies, and ADCs.

More information is available at www.sorrentotherapeutics.com.

SOURCE Sorrento Therapeutics, Inc.